血塞通注射液辅助依达拉奉对急性期糖尿病性脑梗死疗效影响及安全性研究  

Effect and safety of Xuesaitong injection assisted edaravone on acute diabetic cerebral infarction

作　　者：李小玉 章鹏 何小庆 王英 王元伟 LIXiaoyu;ZHANG Peng;HEXiaoqing;WANG Ying;WANG Yuanwei(Department of Neurology,Shuyang Hospital Affiliated to Yangzhou University Medical College,Suqian Jiangsu 223600,China)

机构地区：[1]扬州大学医学院附属沭阳医院神经内科,江苏宿迁223600 [2]徐州医科大学附属沭阳医院神经内科,江苏宿迁223600

出　　处：《中国急救复苏与灾害医学杂志》2022年第9期1174-1177,共4页China Journal of Emergency Resuscitation and Disaster Medicine

基　　金：2019年宿迁市科技计划项目(编号:Z2019019);江苏省第五期“333高层次人才培养工程”科研资助项目(编号:BRA2019231)。

摘　　要：目的探讨血塞通注射液辅助依达拉奉对急性期糖尿病性脑梗死(ACI)疗效影响及安全性。方法选取2018年4月—2020年10月扬州大学医学院附属沭阳医院收治的112例急性期糖尿病性ACI患者为研究对象,以随机数字表法分研究组、对照组,每组各56例。对照组行常规治疗联合依达拉奉,研究组在对照组的基础上另给予血塞通注射液治疗。比较两组临床疗效及治疗前后(结束治疗后次日)神经功能,统计两组患者血液流变学及血清因子变化及情况,记录治疗期间药物安全性。结果两组治疗后的美国国立卫生院卒中量表(NIHSS)评分均低于治疗前(P<0.05),研究组治疗后的NIHSS评分低于对照组(P<0.05)。研究组总有效率高于对照组(P<0.05)。两组治疗后的血浆黏度、全血高切黏度、全血低切黏度均低于治疗前(P<0.05),且研究组治疗后的上述指标均低于对照组(P<0.05)。两组治疗后的OX40配体(OX40L)、神经视锥蛋白样蛋白-1(VILIP-1)水平均低于治疗前(P<0.05),且研究组治疗后的OX40L、VILIP-1水平均低于对照组(P<0.05)。两组总不良反应发生率对比差异无统计学意义(P>0.05)。结论血塞通注射液辅助依达拉奉对急性期糖尿病性ACI可减轻患者神经功能损伤,增强治疗效果,改善血液流变学及血清因子状况,且安全性良好。Objective To explore the effects and safety of Xuesaitong injection assisted edaravone on acute diabetic cerebral infarction(ACI).Methods A total of 112 patients with acute-stage diabetic ACI were randomly divided into 2 equal groups:control group receiving conventional treatment combined with intravenous drip of edaravone 30 mg/d for 2 weeks,and study group receivingthe above mentioned treatment and intravenous drip of 400 mg Xuesaitong per day in addition for 2 weeks.Before and 1 days after treatment National Institutes of Health Stroke Scale(NIHSS)was used to evaluate the neurological function,and peripheral venous blood samples were collected to test the plasma viscosity,whole blood high-shear viscosity,and whole blood low-shear viscosity by automatic blood rheometer,and to measure the levels of OX40 ligand(OX40L)and neurotrypsin-like protein-1(VILIP-1).Results The NIHSS scores after treatment of the two groups were both lower than those before treatment(both P<0.05),and the NIHSS scores after treatment of the study group wassignificantly lower than that of the control group(P<0.05).The total effective rate of the study group was significantly higher than that of the control group(P<0.05).The levels of plasma viscosity,whole blood high-shear viscosity,and whole blood low-shear viscosity after treatment were all significantly lower than those before treatment(all P<0.05),and the above-mentioned hemorheological indexes after treatment of the study group were all lower than those of the control group(all P<0.05).The levels of OX40L and VILIP-1 after treatment of the two groups were all significantly lower than those before treatment(all P<0.05),and the levels of OX40L and VILIP-1 after treatment of the study group were both significantly lower than those of the control group(all P<0.05).There was no significant difference in the incidence of total adverse reactions between the two groups(P>0.05).Conclusion Combined use of Xuesaitong injection and edaravone can reduce the neurological damage,enhance the treatment

关 键 词：血塞通注射液 依达拉奉 糖尿病 脑梗死 疗效 安全性 

分 类 号：R743.33[医药卫生—神经病学与精神病学]